Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A breast cancer gene signature for indolent disease.

Breast cancer research and treatment - 1 Jul 2017

Delahaye Leonie J M J, Drukker Caroline A, Dreezen Christa, Witteveen Anke, Chan Bob, Snel Mireille, Beumer Inès J, Bernards Rene, Audeh M William, Van't Veer Laura J, Glas Annuska M

Abstract excerpt

PURPOSE: Early-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to chemotherapy, long-term adherence may be low due to potential adverse side effects as well as compliance fatigue. It is of high clinical utility to identify subgroups...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Regulatory Networks

Share to Kaplan-Meier Estimate

Share to Precision Medicine

Share to Prognosis

Share to Risk Assessment

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 28451965
DOI: 10.1007/s10549-017-4262-0
PMCID: PMC5487706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A breast cancer gene signature for indolent disease.PMID 28451965Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read ↗

Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity Read ↗

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsSemantic proximity Read ↗

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signatureSemantic proximity Read ↗

A Gene Signature for Predicting Outcome in Patients with Basal-like Breast CancerSemantic proximity Read ↗

Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Semantic proximity Read ↗

ENDORSE: a prognostic model for endocrine therapy response in advanced estrogen-receptor positive breast cancersSemantic proximity Read ↗

Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up.Semantic proximity Read ↗

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerSemantic proximity Read ↗

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.